Sintx Guides Q3 Revenue $900K-$1.1M, Q4 $1.0M-$1.3M; Completes 3D Printing Facility
SINT sits 43% above its 52-week low of $1.4 on elevated volume (31× avg).
Summary
Sintx Technologies issued a mid-year business update with first-time quarterly revenue guidance, completion of a 3D printing facility, and strategic advisor engagement, while continuing to manage liquidity and going concern risks.
Key Events · Earnings and Guidance · SINT
-
First Revenue Guidance Issued
Sintx expects Q3 2026 revenue of $900K-$1.1M and Q4 2026 revenue of $1.0M-$1.3M, driven by $3.2M in industrial purchase orders with shipments commencing.
-
3D Printing Facility Completed
The advanced 3D printing manufacturing facility for SiNERGY patient-specific implants is now complete, expanding vertically integrated production capabilities.
-
Strategic Advisor Engaged
Chris Lyons of Southern Metrics was engaged to evaluate inbound strategic opportunities including partnerships, licensing, and business development.
-
NIH Grant Extended
The NIH granted an additional 12-month access period to ~$745K remaining on a $1.97M grant for porous silicon nitride/PEEK spinal fusion implant development.
Analysis · SINT · Industrial Applications And Services
Sintx provided its first specific quarterly revenue guidance, projecting $900K-$1.1M in Q3 and $1.0M-$1.3M in Q4, driven by $3.2M in industrial purchase orders. The company also completed its advanced 3D printing facility, engaged a strategic advisor, and secured an NIH grant extension. These developments signal a shift toward commercial execution, but the company remains dependent on additional financing with going concern doubts still outstanding.
At the time of this filing, SINT was trading at $2.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $11.3M. The 52-week trading range was $1.40 to $6.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.